AI-designed lipids matched flu protection with 100× less mRNA
This week brought major breakthroughs in mRNA delivery: scientists cracked the code on making vaccines work at much lower doses and solved the durability problem that's been holding back linear mRNA therapeutics.
🎯 AI-designed lipids make mRNA vaccines 100x more potent
Scientists developed a new class of degradable, cyclic amino ionizable lipids that delivered the same protective flu vaccine response at a 100-fold lower dose compared to the FDA-approved lipid SM-102
The top performer, AMG1541, substantially reduced liver expression after intramuscular injection while improving mRNA delivery to immune cells at injection sites and lymph nodes
In mice, this led to stronger germinal center reactions (where antibodies mature) and enhanced clearance of the lipid from the body, potentially reducing toxicity
Why it matters: Lower doses could make mRNA vaccines cheaper, safer, and more accessible globally while reducing side effects.
Key Findings
🧬 Viral RNA sequences make mRNA last weeks instead of days
Researchers screened 196,277 viral sequences and found 11 elements that dramatically enhance mRNA stability and translation
The top element (A7) makes linear mRNA as stable as circular RNA while achieving higher protein production
In mouse liver, A7-containing mRNA maintained protein expression for over 2 weeks, substantially outperforming circular RNA
🔬 Sugar-based lipids replace problematic PEG without losing effectiveness
Scientists created glycolipids using maltoheptaose (a sugar chain) that successfully replaced PEG lipids in mRNA delivery systems
The glycolipid formulations (G7B2) significantly enhanced spleen targeting while minimizing anti-PEG antibody production
Unlike PEG-based systems, these maintained consistent delivery efficiency over repeated doses and showed robust anti-tumor effects in melanoma models
🎯 Heart-targeting screen reveals acid-sensitive lipids work best
Using a cardiac tissue model made from human stem cells, researchers identified lipid formulations that efficiently penetrate 3D heart tissue
Acid-degradable PEG-lipids showed superior heart transfection with reduced liver uptake when tested in mice
The tissue model successfully predicted which formulations would work best in living animals
🧪 Circular RNA cancer vaccine outperforms traditional mRNA
A circular RNA vaccine targeting liver cancer protein GPC3 demonstrated sustained antigen production and more potent immune responses than standard mRNA vaccines
When combined with a immune stimulant, the treatment effectively suppressed tumor growth in liver cancer models
Single-cell analysis revealed the vaccine enhanced antigen presentation and strengthened immune cell interactions
📊 Three COVID shots before infection cut long COVID risk by 34%
Analysis of 4,809 individuals found that receiving at least three COVID-19 vaccine doses before infection reduced long COVID symptoms by 34% compared to being unvaccinated
The protective effect remained stable over two years of follow-up, with vaccine effectiveness against long COVID estimated at 26.5%
Post-infection vaccination showed no association with long COVID outcomes, emphasizing the importance of pre-exposure protection
🔬 Self-regulating microfluidics automate nanoparticle optimization
Scientists developed a fully automated system that uses machine learning to optimize lipid nanoparticle formulations in real-time
The system combines computational fluid dynamics simulations with experimental screening to predict critical properties like size and drug loading
This eliminates the need for human intervention during the optimization process, potentially accelerating nanoparticle discovery
Implications
These advances collectively address mRNA therapy's biggest challenges: making treatments work at lower doses, last longer in the body, avoid immune reactions, and target specific organs. The combination of AI-designed delivery systems and automated optimization platforms could accelerate the next generation of RNA medicines.
Studies in this issue
Primary sources used for this newsletter.
- Breakdown-Friendly Ionizable Lipids for Strong Influenza mRNA Vaccinesmain storyNature nanotechnology2025-11-07PMID 41203968
- RNA stabilizers for long-lasting modified mRNA medicineskey findingNature biotechnology2025-11-07PMID 41203992
- Using Glycolipids Instead of PEG Lipids in Lipid Nanoparticles for mRNA Deliverykey findingJournal of the American Chemical Society2025-11-04PMID 41186003
- Self-controlling microfluidic system for making lipid nanoparticleskey findingJournal of controlled release : official journal of the Controlled Release Society2025-11-03PMID 41183573
- A lab model for testing fat-based mRNA delivery predicts how well it works in the heartkey findingNature biomedical engineering2025-11-03PMID 41184608
- Best timing of the Pfizer COVID-19 vaccine to reduce long COVID and related quality of life losskey findingCommunications medicine2025-11-07PMID 41204001
- Circular RNA vaccine targeting GPC3 may slow liver cancer by boosting the immune systemkey findingHepatology (Baltimore, Md.)2025-11-07PMID 41201153
Continue reading
All mRNA Technology issuesGet the next mRNA Technology issue
Seven papers, once a week. Free.